Free NY MPJE Exam Flashcards

NYSED, acting through the Board of Regents and Office of the Professions, grants pharmacist licenses and registers pharmacies. The State Board of Pharmacy advises and assists the Regents and Department; it does not independently issue licenses.

The applicant must be at least 21, be of good moral character, and satisfy New York's education, examination, and experience requirements. Meeting an NABP exam requirement alone does not create a New York license.

New York requires the NAPLEX and the New York-specific MPJE. An MPJE or UMPJE result from another jurisdiction does not substitute for the NY MPJE.

NYSED requires both the NAPLEX and NY MPJE to be passed within five years of application. A candidate should distinguish this licensure timing rule from NABP's separate retake rules.

No. NYSED lists route-specific requirements: certain accredited non-PharmD graduates need six months or 1,040 hours; non-accredited graduates need 12 months or 2,080 hours; PharmD graduates are exempt from a separate experience requirement because the program includes it.

No. NYSED stopped requiring Part III for pharmacist licensure on January 1, 2022. Current applicants should not treat legacy Part III material as a present examination step.

It permits supervised practice of pharmacy within the permit's terms. It is not an independent pharmacist license: the intern must work under an authorized pharmacist preceptor and may not practice alone.

A pharmacist may supervise no more than one full-time intern or two part-time interns. Interns must remain under the required supervision and are not counted as registered pharmacy technicians.

The pharmacist needs 45 hours, including at least 23 live hours and no more than 22 self-study hours. Within the 45 are three hours on medication/prescription error reduction and three hours on compounding. Current through August 1, 2026.

An RPhT is licensed under Article 137-A and may perform authorized compounding, preparing, labeling, or dispensing assistance under direct personal pharmacist supervision when no professional judgment is required. Judgment tasks such as interpreting prescriptions, receiving oral prescriptions, and counseling remain outside that scope.

One pharmacist may directly supervise no more than two RPhTs performing their authorized scope tasks and no more than four total persons at one time. Pharmacy interns do not count toward that four-person total.

Identify every applicable rule and follow the controlling rule that is more restrictive unless federal law preempts the state rule. NABP tests federal and state law together and instructs candidates to answer under the prevailing law of the jurisdiction.

Confirm that an authorized practitioner issued it within the practitioner's lawful scope, for a legitimate patient-care purpose, with the required patient, drug, directions, date, and prescriber information. A technically complete document is not valid if the issuer lacked authority or purpose.

A controlled-substance prescription must serve a legitimate medical purpose in the usual course of professional practice. The prescriber bears responsibility, but the pharmacist who fills it has a corresponding responsibility and must resolve red flags rather than dispense knowingly outside that purpose.

Prescribers generally must issue prescriptions electronically, but law recognizes exceptions for specified situations. When a pharmacy receives a permitted written or oral prescription, the pharmacist is not required to verify the prescriber's reason for using an exception.

The initial prescription for an opioid to treat acute pain is limited to a seven-day supply. The rule excludes chronic pain, cancer treatment, hospice or other end-of-life care, and palliative care; a later prescription may follow after professional consultation.

The statutory PMP consultation duty generally applies to practitioners before prescribing Schedule II, III, or IV controlled substances, subject to exceptions. Pharmacies have a separate duty to report dispensed Schedule II through V data to the state, generally within 24 hours after delivery.

Before dispensing for a new pharmacy patient, a new medication for an existing patient, or a change in dose, strength, route, or directions, the pharmacist or intern must personally counsel the patient or authorized representative, face-to-face when practicable or by telephone.

The pharmacy must provide a written offer to counsel and a telephone number at which a pharmacist or intern is available. If counseling is requested, it must be provided personally by an authorized pharmacist or intern, not delegated to support staff.

The pharmacist must use professional judgment to resolve the concern. When the law requires patient contact or an offer to counsel because of a significant potential problem, that step occurs before dispensing rather than being replaced by a routine printed leaflet.

Yes. The pharmacist or intern may fill the prescription as presented after a refusal, provided the refusal to give profile information or accept counseling is documented in the pharmacy's records.

The patient must give express written consent for access to confidential medication information in a shared database. Operational convenience or a general assumption of consent does not replace that authorization.

No. CDTM operates within an authorized written agreement or protocol and patient-specific order. The pharmacist may manage or adjust therapy only within that authority and must document changes; selection of a different drug requires express authorization.

A covered pharmacy—generally part of a New York group of eight or more pharmacies under common ownership—and a mail-order pharmacy must provide free competent interpretation and translation services to limited-English-proficient patients as Part 63 specifies.

No. The pharmacist must also be currently registered and NYSED-certified to immunize. Current law permits certified pharmacists to administer listed adult vaccines and influenza vaccine to patients age two or older under patient-specific or non-patient-specific orders; product-specific requirements still apply.

Yes. NYSDOH's statewide pharmacy standing order permits New York pharmacies to dispense naloxone under a non-patient-specific prescription and protocol. The standing-order page was revised in February 2026 and applies to all New York pharmacies.

The pharmacist must be licensed and located in New York, complete the required training, follow the state assessment and treatment pathway, and act under a qualifying non-patient-specific order. The pharmacist must notify the patient's primary care practitioner within 72 hours unless a stated exception applies.

Not merely for convenience. The pharmacist needs legal authority, such as prescriber authorization, an authorized substitution rule, or a valid protocol. Any permitted clarification or change must be documented as the governing rule requires.

The record must identify the patient and prescriber, the date, drug and strength, quantity, and directions, plus the prescriber's required authentication and professional identifiers. Controlled substances and special formats add requirements; missing information cannot always be supplied by the pharmacist.

Part 63 identifies patient name, full-sentence directions, and drug name and strength as critical elements. Pharmacy contact information, patient address, prescriber, fill date, and prescription number are important elements; all must appear under the patient-centered labeling rules.

When the prescription permits substitution, the pharmacist generally selects a less expensive therapeutically equivalent product under New York's substitution law. A prescriber's legally effective direction against substitution controls, and the dispensed product and required notices must be documented.

No. A pharmacist may substitute only a biological product that meets the legal standard for interchangeability and must follow New York's prescriber-direction, patient-notification, and record requirements. Similarity alone is insufficient.

Effective October 7, 2025, a noncontrolled prescription may be fully transferred with all remaining refills when the patient requests or approves it. Effective April 14, 2026, controlled-prescription transfers are also allowed subject to Public Health Law Article 33, Part 80, federal law, and pharmacist-to-pharmacist record rules.

No. Schedule II prescriptions have no refills. A prescriber may issue multiple separate prescriptions when federal conditions are met, but those are distinct prescriptions rather than refills of one order.

They may be refilled no more than five times within six months after issuance. New York requirements still apply, and an authorization beyond either limit requires a new prescription.

The pharmacist must create the required record, verify the prescriber and patient in good faith, and limit dispensing to a five-day supply. The prescriber must provide the follow-up written or electronic prescription within 72 hours; if it is not received, the pharmacist must notify NYSDOH within seven days.

Different legal pathways have different deadlines. A shortage remainder generally must be supplied within 72 hours, while patient-requested partial fills and special rules for terminally ill, hospice, or residential-health-care-facility patients have their own time and documentation requirements.

The federal Poison Prevention Packaging Act permits recognized exceptions, including a prescriber's direction for a particular prescription or a patient's blanket request for non-child-resistant containers. Otherwise, covered products require compliant special packaging.

Covered products are kept behind the counter or in locked storage. The seller verifies qualifying photo identification, records the transaction in the required logbook, enforces quantity limits, and completes required employee training under the Combat Methamphetamine Epidemic Act.

The pharmacy generally must transmit Schedule II through V dispensing information to NYSDOH no later than 24 hours after the drug is delivered to the patient or representative. This reporting duty is distinct from a practitioner's PMP consultation duty.

They regulate different actors and activities: NYSED licenses the individual pharmacist, New York registers the pharmacy establishment, and DEA registration authorizes controlled-substance activity at the federal level. One credential does not replace the others.

The pharmacy must be under the immediate supervision and management of a licensed pharmacist while open for business. A pharmacist may not simultaneously supervise more than one pharmacy.

Five years is the recurring New York rule for prescription records and retrievable patient medication profiles. A pharmacy must preserve readability, retrievability, audit trails, and any longer or more specific record requirement that applies.

Take an initial inventory when controlled-substance activity begins and a new inventory at least every two years. Schedule II quantities require an exact count or measure; Schedule III through V may generally be estimated unless a container holds more than 1,000 tablets or capsules.

Use an executed DEA Form 222 or its electronic equivalent through the Controlled Substance Ordering System. Schedule III through V purchases do not use Form 222, but invoices and required controlled-substance records must be maintained.

Notify the DEA field division in writing within one business day of discovery and complete DEA Form 106 electronically for the theft or significant loss. Also follow New York notification, investigation, and record requirements; do not delay initial notice until the investigation is complete.

Participating pharmacies must be New York-registered and connected by common ownership or a written contract. They must maintain required records for five years, identify participating pharmacies on labels, give notice and obtain one-time patient consent, and honor a patient's opt-out.

No. A nonresident pharmacy serving New York patients must register with NYSED and meet New York's nonresident-pharmacy duties, including patient access to a pharmacist and required labeling and records. Home-state authority alone is insufficient.

Compounding must be performed by authorized personnel under required supervision, from lawful ingredients, for a valid patient-care basis or permitted anticipation, using applicable sterile or nonsterile standards. The pharmacy must document formulations, ingredients, calculations, procedures, quality controls, and assigned dating.

The owner must notify NYSED as required, secure and lawfully transfer or dispose of drugs, preserve or transfer prescription and patient records, provide patient notice and access, surrender the registration, and separately satisfy DEA and NYSDOH controlled-substance duties.